MBC Pharma

MBC Pharma, Inc. is a pharmaceutical company focused on discovering and developing novel medicines for the treatment of oncology, bone, and infectious diseases. The company's core technology revolves around improving known drugs by adding tissue targeting capabilities and increasing cancer cell specificity and uptake. MBC Pharma's research and development programs are built upon two proprietary discovery platforms.

The company's primary innovation is its bone-targeting technology, which leverages the bone-seeking properties of bisphosphonates to deliver drugs to the bone microenvironment. This approach is particularly significant in addressing Cancer Induced Bone Disease, a major cause of morbidity and mortality in cancer patients. More than half of all carcinoma patients develop bone metastases, and current therapies are only palliative. Traditional chemotherapies struggle to reach effective concentrations in the bone and its microenvironment, which is crucial for cancer progression.

MBC Pharma's proprietary molecular design links a bisphosphonate (the bone-targeting component commonly used as an osteoporosis drug) to a chemotherapy moiety via a phosphate group. After intravenous administration, this conjugate binds to bone, where both drugs are then released. The concentrated drug near the bone drives uptake into bone-localized cancer cells and osteoclasts (bone-resorbing cells). This approach allows the conjugates to localize at sites of bone destruction induced by tumor cells, providing a unique combination of anti-resorptive properties and increased local concentration of cytotoxic agents. The result is greatly improved efficacy without increasing systemic toxicity.